[1] Schwab, I. and Nimmerjahn, F. (2013) Intravenous Immunoglobulin Therapy: How Does IgG Modulate the Immune System? Nature Review Immunology, 13, 176-189.
http://dx.doi.org/10.1038/nri3401
[2] Gelfand, E.W. (2012) Intravenous Immune Globulin in Autoimmune and Inflammatory Diseases. New England Journal of Medicine, 367, 2015-2025.
http://dx.doi.org/10.1056/NEJMra1009433
[3] Aschermann, S., Lux, A., Baerenwaldt, A., Biburger, M. and Nimmerjahn, F. (2010) The Other Side of Immunoglobulin G: Suppressor of Inflammation. Clinical and Experimental Immunology, 160, 161-167.
http://dx.doi.org/10.1111/j.1365-2249.2009.04081.x
[4] Salfeld, J.G. (2007) Isotype Selection in Antibody Engineering. Nature Biotechnology, 25, 1369-1372.
http://dx.doi.org/10.1038/nbt1207-1369
[5] von Gunten, S., Smith, D.F., Cummings, R.D., Riedel, S., Miescher, S., Schaub, A., Hamilton, R.G. and Bochner, B.S. (2009) Intravenous Immunoglobulin Contains a Broad Repertoire of Anticarbohydrate Antibodies That Is Not Restricted to the IgG(2) Subclass. Journal of Allergy and Clinical Immunology, 123, 1268-1276.
http://dx.doi.org/10.1016/j.jaci.2009.03.013
[6] van der Neut Kolfschoten, M., Schuurman, J., Losen, M., et al. (2007) Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange. Science, 317, 1554-1557.
http://dx.doi.org/10.1126/science.1144603
[7] Burton, D.R. and Wilson, I.A. (2007) Immunology. Square-Dancing Antibodies. Science, 317, 1507-1508.
http://dx.doi.org/10.1126/science.1148905
[8] Rispens, T., Ooijevaar-de Heer, P., Bende, O. and Aalberse, R.C. (2011) Mechanism of Immunoglobulin G4 Fab-Arm Exchange. Journal of the American Chemical Society, 133, 10302-10311.
[9] Nirula, A., Glaser, S.M., Kalled, S.L. and Taylor, F.R. (2011) What Is IgG4? A Review of the Biology of a Unique Immunoglobulin Subtype. Current Opinion in Rheumatology, 23, 119-124.
http://dx.doi.org/10.1097/BOR.0b013e3283412fd4
[10] Wang, W. and Li, J. (2011) Identification of Natural Bispecific Antibodies against Cyclic Citrullinated Peptide and Immunoglobulin G in Rheumatoid Arthritis. PLoS One, 6, e16527.
http://dx.doi.org/10.1371/journal.pone.0016527
[11] Ebbo, M., Daniel, L., Pavic, M., et al. (2012) IgG4-Related Systemic Disease: Features and Treatment Response in a French Cohort: Results of a Multicenter Registry. Medicine, 91, 49-56.
http://dx.doi.org/10.1097/MD.0b013e3182433d77
[12] Ebbo, M., Grados, A., Daniel, L., Vely, F., Harle, J.R., Pavic, M. and Schleinitz, N. (2012) IgG4-Related Systemic Disease: Emergence of a New Systemic Disease? Literature Review. La Revue de Médecine Interne, 33, 23-34.
http://dx.doi.org/10.1016/j.revmed.2011.08.012
[13] Zen, Y. and Nakanuma, Y. (2010) IgG4-Related Disease: A Cross-Sectional Study of 114 Cases. American Journal of Surgical Pathology, 34, 1812-1819.
http://dx.doi.org/10.1097/PAS.0b013e3181f7266b
[14] Maehara, T., Moriyama, M., Nakashima, H., Miyake, K., Hayashida, J.N., Tanaka, A., Shinozaki, S., Kubo, Y. and Nakamura, S. (2012) Interleukin-21 Contributes to Germinal Centre Formation and Immunoglobulin G4 Production in IgG4-Related Dacryoadenitis and Sialoadenitis, So-Called Mikulicz’S Disease. Annals of the Rheumatic Diseases, 71, 2011-2020.
http://dx.doi.org/10.1136/annrheumdis-2012-201477
[15] von Gunten, S., Schaub, A., Vogel, M., Stadler, B.M., Miescher, S. and Simon, H.U. (2006) Immunologic and Functional Evidence for Anti-Siglec-9 Autoantibodies in Intravenous Immunoglobulin Preparations. Blood, 108, 4255-4259.
http://dx.doi.org/10.1182/blood-2006-05-021568
[16] Gelfand, E.W. (2001) Antibody-Directed Therapy: Past, Present, and Future. Journal of Allergy and Clinical Immunology, 108, S111-S116.
http://dx.doi.org/10.1067/mai.2001.117824
[17] Sewell, W.A.C. and Jolles, S. (2002) Immunomodulatory Action of Intravenous Immunoglobulin. Immunology, 107, 387-393.
http://dx.doi.org/10.1046/j.1365-2567.2002.01545.x
[18] Lamoureux, J., Aubin, E. and Lemieux, R. (2004) Autoantibodies Purified from Therapeutic Preparations of Intravenous Immunoglobulins (IVIg) Induce the Formation of Autoimmune Complexes in Normal Human Serum: A Role in the in Vivo Mechanisms of Action of IVIg? International Immunology, 16, 929-936.
http://dx.doi.org/10.1093/intimm/dxh094
[19] Dimitrov, J.D., Planchais, C., Kang, J., Pashov, A., Vassilev, T.L., Kaveri, S.V. and Lacroix-Desmazes, S. (2010) Heterogeneous Antigen Recognition Behavior of Induced Polyspecific Antibodies. Biochemical and Biophysical Research Communications, 398, 266-271.
http://dx.doi.org/10.1016/j.bbrc.2010.06.073
[20] Bussone, G., Dib, H., Dimitrov, J.D., Camoin, L., Broussard, C., Tamas, N., Guillevin, L., Kaveri, S.V. and Mouthon, L. (2009) Identification of Target Antigens of Self-Reactive IgG in Intravenous Immunoglobulin Preparations. Proteomics, 9, 2253-2262.
http://dx.doi.org/10.1002/pmic.200800819
[21] Schaub, A., Wymann, S., Heller, M., Ghielmetti, M., Beleznay, Z., Stadler, B.M., Bolli, R. and Miescher, S. (2007) Self-Reactivity in the Dimeric Intravenous Immunoglobulin Fraction. Annals of the New York Academy of Sciences, 1110, 681-693.
http://dx.doi.org/10.1196/annals.1423.071
[22] Néron, S. and Roy, A. (2012) Overview of IgG-Reactivity in Therapeutic Immunoglobulins Revealed by Protein Array Analysis. Biochemistry & Analytical Biochemistry, S8, 001.
[23] Ballow, M. (2011) The IgG Molecule as a Biological Immune Response Modifier: Mechanisms of Action of Intravenous Immune Serum Globulin in Autoimmune and Inflammatory Disorders. Journal of Allergy and Clinical Immunology, 127, 315-323.
http://dx.doi.org/10.1016/j.jaci.2010.10.030
[24] Tha-In, T., Bayry, J., Metselaar, H.J., Kaveri, S.V. and Kwekkeboom, J. (2008) Modulation of the Cellular Immune System by Intravenous Immunoglobulin. Trends in Immunology, 29, 608-615.
http://dx.doi.org/10.1016/j.it.2008.08.004
[25] de Grandmont, M.J., Racine, C., Roy, A., Lemieux, R. and Néron, S. (2003) Intravenous Immunoglobulins Induce the in Vitro Differentiation of Human B Lymphocytes and the Secretion of IgG. Blood, 101, 3065-3073.
http://dx.doi.org/10.1182/blood-2002-06-1684
[26] Siegel, J. (2005) Immune Globulins: Therapeutic, Pharmaceutical, Cost, and Administration Considerations. Pharmacy Practice News, Special Edition, 15-19.
[27] Kaushik, A., Lim, A., Poncet, P., Ge, X.R. and Dighiero, G. (1988) Comparative Analysis of Natural Antibody Specificities among Hybridomas Originating from Spleen and Peritoneal Cavity of Adult NZB and BALB/c Mice. Scandinavian Journal of Immunology, 27, 461-471.
http://dx.doi.org/10.1111/j.1365-3083.1988.tb02372.x
[28] Li, Y., Nishihara, E. and Kakudo, K. (2011) Hashimoto’s Thyroiditis: Old Concepts and New Insights. Current Opinion in Rheumatology, 23, 102-107.
http://dx.doi.org/10.1097/BOR.0b013e328341378c
[29] Adler, T.R., Beall, G.N., Curd, J.G., Heiner, D.C. and Sabharwal, U.K. (1984) Studies of Complement Activation and IgG Subclass Restriction of Anti-Thyroglobulin. Clinical and Experimental Immunology, 56, 383-389.
[30] Liu, W., Meckel, T., Tolar, P., Sohn, H.W. and Pierce, S.K. (2010) Intrinsic Properties of Immunoglobulin IgG1 Isotype-Switched B Cell Receptors Promote Microclustering and the Initiation of Signaling. Immunity, 32, 778-789.
http://dx.doi.org/10.1016/j.immuni.2010.06.006
[31] Xie, L.-D., Gao, Y., Li, M.-R., Lu, G.Z. and Guo, X.-H. (2008) Distribution of Immunoglobulin G Subclasses of Anti- Thyroid Peroxidase Antibody in Sera from Patients with Hashimoto’s Thyroiditis with Different Thyroid Functional Status. Clinical & Experimental Immunology, 154, 172-176.
http://dx.doi.org/10.1111/j.1365-2249.2008.03756.x
[32] Zhang, Y., Gao, Y., Li, M., Xie, L., Huang, Y. and Guo, X. (2010) Avidity of Thyroglobulin Antibody in Sera from Patients with Hashimoto’s Thyroiditis with Different Thyroid Functional Status. Clinical and Experimental Immunology, 161, 65-70.
[33] Dietrich, G. and Kazatchkine, M.D. (1990) Normal Immunoglobulin G (IgG) for Therapeutic Use (Intravenous Ig) Contain Antiidiotypic Specificities against an Immunodominant, Disease-Associated, Cross-Reactive Idiotype of Human Anti-Thyroglobulin Autoantibodies. The Journal of Clinical Investigations, 85, 620-625.
http://dx.doi.org/10.1172/JCI114483
[34] Dietrich, G., Piechaczyk, M., Pau, B. and Kazatchkine, M.D. (1991) Evidence for a Restricted Idiotypic and Epitopic Specificity of Anti-Thyroglobulin Autoantibodies in Patients with Autoimmune Thyroiditis. European Journal of Immunology, 21, 811-814.
http://dx.doi.org/10.1002/eji.1830210340
[35] Dietrich, G., Varela, F.J., Hurez, V., Bouanani, M. and Kazatchkine, M.D. (1993) Selection of the Expressed B Cell Repertoire by Infusion of Normal Immunoglobulin G in a Patient with Autoimmune Thyroiditis. European Journal of Immunology, 23, 2945-2950.
[36] Rossi, F. and Kazatchkine, M.D. (1989) Antiidiotypes against Autoantibodies in Pooled Normal Human Polyspecific Ig. The Journal of Immunology, 143, 4104-4109.
[37] Nezlin, R. (2010) Interactions between Immunoglobulin G Molecules. Immunology Letters, 132, 1-5.
http://dx.doi.org/10.1016/j.imlet.2010.06.006
[38] Aalberse, R.C., Stapel, S.O., Schuurman, J. and Rispens, T. (2009) Immunoglobulin G4: An Odd Antibody. Clinical and Experimental Allergy, 39, 469-477.
http://dx.doi.org/10.1111/j.1365-2222.2009.03207.x
[39] Rispens, T., Ooievaar-De Heer, P., Vermeulen, E., Schuurman, J., van der Neut Kolfschoten, M. and Aalberse, R.C. (2009) Human IgG4 Binds to IgG4 and Conformationally Altered IgG1 via Fc-Fc Interactions. The Journal of Immunology, 182, 4275-4281.
http://dx.doi.org/10.4049/jimmunol.0804338
[40] Lamoureux, J., Aubin, E. and Lemieux, R. (2003) Autoimmune Complexes in Human Serum in Presence of Therapeutic Amounts of Intravenous Immunoglobulins. Blood, 101, 1660-1662.
http://dx.doi.org/10.1182/blood-2002-08-2598